Are the body shape index, the body roundness index and waist-to-hip ratio better than BMI to predict recurrent pregnancy loss?

Tunay Kiremitli1 | Sevil Kiremitli1 | Pasa Ulug1 | Kemal Dinc1 | Kemine Uzel1 | Yusuf Kemal Arslan2

1Medical Faculty, Obstetrics and Gynaecology Department, Erzincan Binali Yildirim University, Erzincan, Turkey
2Biostatistics Department, Medical Faculty, Erzincan Binali Yildirim University, Erzincan, Turkey

Correspondence
Tunay Kiremitli, Erzincan Binali Yildirim University, Mengucek Gazi Training and Research Hospital Central/ Erzincan, Turkey.
Email: tkiremitli@hotmail.com

Abstract

Purpose: Etiology could not be determined in approximately 50% of recurrent pregnancy loss cases, and it was named unexpected recurrent pregnancy loss (URPL). A body shape index (ABSI), body roundness index (BRI), and waist-to- hip ratio (WtHR) are new indexes that are superior to BMI in showing body fat distribution. We aimed to investigate the potency of ABSI, BRI, and WtHR in URPL, their superiority to BMI, and their suitability for clinical use.

Methods: One hundred and thirty-eight patients between the ages of 20-40 who applied to our hospital for URPL between January 2016 and December 31, 2020 were included in our study. Weight, height, waist circumference, and hip circumference were measured, and indexes were calculated. Differences between the URPL and control groups were calculated using the IBM SPSS program.

Results: There was a significant difference between the two groups for BRI, ABSI, and WtHR values, while there was no significant difference in BMI. BRI (4.4 ± 1.7 vs 3.9 ± 1.5), ABSI (0.08 ± 0.005 vs 0.078 ± 0.004), and WtHR (0.84 ± 0.06 vs 0.82 ± 0.05) values were higher in the URPL group. ROC analysis showed us that BRI, ABSI, and WtHR have a diagnostic value for URPL (P < .05). When indexes were above the cutoff values, RPL risk increased 3.59 times in ABSI, 2.26 times in BRI, and 2.9 times in WtHR (P < .05).

Conclusions: The relationship between obesity and URPL can be explained more clearly by using effective indexes that show body fat distribution rather than BMI. Ethics committee approval was obtained from Erzincan Binali Yildirim University in 14.01.2021. Clinical Research Ethics Committee no: 01/01.

Keywords
a body shape index, body mass index, body roundness index, recurrent pregnancy loss, waist-to-hip ratio
1 | INTRODUCTION

The spontaneous termination of pregnancy before the 20th week and when the fetal weight is below 500 g is called “abortion,” and about 15%-25% of known pregnancies will end in a miscarriage. Recurrent pregnancy loss (RPL) has been defined as the loss of three or more consecutive pregnancies before the 20th gestational week.

The etiology of RPL includes immunological, genetic, endocrine, anatomical, environmental factors, and infections. Despite all these investigations, etiology could not be determined in approximately 50% of RPL cases, and it was named unexpected recurrent pregnancy loss (URPL).

Obesity is a chronic disease characterized by an increase in body fat mass since the energy taken into the body is greater than the energy consumed. Obesity is determined by the measurement of body mass index (BMI). The World Health Organization defined a BMI of 25 and above as overweight and 30 and above as obesity.

In the literature, studies have reported that infertility, abortion, recurrent pregnancy losses, and failure rates in assisted reproductive techniques increase in obese patients. It has been found that many chronic diseases, especially diabetes and cardiac diseases, are related to body fat distribution and fat percentage rather than the weight-height ratio. MRI, bio-impedance analysis, air displacement plethysmography, and dual-energy X-ray absorptiometry are direct methods used to show body fat distribution. However, researchers have been canalized to new indirect methods that can be applied more easily, since direct methods are not practical in the clinic, their cost is high, and experienced personnel are needed for shooting and interpretation.

It has been reported that waist circumference (WC) and waist-to-hip ratio (WtHR) are superior to BMI in showing cardiometabolic diseases. Based on this, an index named a body shape index (ABSI) was developed by Krakauer NY and Krakauer JC in 2012, and it was determined that it is superior to BMI and WC alone in showing premature mortality. The Body Roundness Index (BRI), which was developed in 2013 by Thomas et al. has modeled the human body as an ellipse and considered it in two axes: the major axis consisting of height and the minor axis consisting of waist and hip. They defined the degree of body roundness as “eccentricity” between 1 and 16. Values approaching 1 indicate thin and narrow elliptical-shaped bodies, while values close to 16 indicate bodies with round and wide elliptical shapes. It has been reported that BRI is more sensitive than BMI and WC in predicting metabolic syndrome and dyslipidemia.

Ovarian reserve expresses the reproductive potential of the woman in terms of number and quality. Follicle stimulating hormone (FSH), estradiol (E₂), antimullerian hormone (AMH) are some tests used for determining ovarian reserve. Obesity has been associated with a decreased ovarian reserve and impaired oocyte quality by affecting follicle functions and development. Studies concluding that decreased ovarian reserve may cause RPL and infertility as a result of the effect on oocyte quality and number are available in the literature.

One of the important underlying factors of central obesity is leptin/adiponectin imbalance, which has been reported to be effective in determining the prognosis of diseases associated with abdominal obesity. Besides its role in fetal growth and development, leptin also has a modulator role for syncytiotrophoblasts. It takes part in autocrine / paracrine events in implantation and the continuation of pregnancy. It was thought that the impairment of leptin balance and the resulting leptin resistance may be associated with poor reproductive performance and miscarriage. In light of this information, in this study, we aimed to investigate the potency of ABSI, BRI, and WtHR in URPL cases, as well as their superiority to BMI, their suitability for clinical use, and their effects on ovarian reserve.

2 | MATERIALS AND METHODS

One hundred and thirty-eight patients between the ages of 20-40 who applied to our hospital for URPL between January 2016 and December 2020 were included in our study. Their files were reviewed retrospectively. The study was conducted in accordance with the principles of the Declaration of Helsinki. Ethics committee approval was obtained from Erzincan Binali Yıldırım University in 14.01.2021. Clinical Research Ethics Committee no: 01/01.

Patients included had a normal hereditary, acquired thrombophilia panels and autoantibody tests, no abnormal maternal and paternal karyotyping, and had the normal results (after 12 hours of fasting) of glucose, TSH, prolactin, and vitamin D tests. All patients were tested for possible intrauterine pathology (endometrial polyp, submucous myoma, intracavitary septum) by transvaginal ultrasonography. Hysteroscopy was performed on suspected patients, and patients with pathology were excluded from the study. Patients with previous ovarian or uterine surgery, endometrioma, menstrual irregularity, polycystic ovaries, smoking or alcohol consumption, history of chemotherapy or radiotherapy, or genetic abnormalities were excluded from the study. The control group included 139 healthy, 20- to 40-year-old patients who had no previous abortion history, did not need assisted reproductive techniques to conceive, and had at least one live birth after 37 weeks of gestation.

2.1 | Calculation of Anthropometric Indexes

The weight of the patients was measured in kg and height in cm. While the patients wore thin clothes for weight measurement, shoes were removed for height measurement. The weight was measured at approximately 0.1 kg. The height was measured at approximately 0.1 cm. Waist circumference was measured over bare skin, midway between the lower rib margin and the iliac crest at the end of expiration. Hip circumference was measured as the maximum
circumference over the buttocks to the nearest 0.1 cm using a soft tape measure.

Women were classified into five BMI groups: underweight (<18.5 kg/m²), normal weight (18.5-24.99 kg/m²), overweight (25-29.99 kg/m²) obese (30-39.9 kg/m²), and massive obesity (≥40 kg/m²) in accordance with the WHO classification of BMI.\(^2\)

Calculation formulas of BMI, WtHR, ABSI and BRI are:

\[
\text{BMI} = \frac{\text{weight(kg)}}{\text{height}^2(m)}
\]

\[
\text{WtHR} = \frac{\text{waist circumference(cm)}}{\text{hip circumference(cm)}}
\]

\[
\text{ABSI} = \frac{\text{wc(cm)}}{(\text{BMI}^2 \times \text{height}^\frac{1}{2})}
\]

\[
\text{BRI} = 364.2 - (365.5 \times \sqrt{1 - \left(\frac{(\text{waist circumference(cm)})}{(0.5 \times \text{height})}ight)^2})
\]

2.2 Statistical analyses

IBM SPSS version 21 (IBM Corp) was used for analyzing data. Descriptive statistics of continuous variables were presented as mean ± standard deviation, median (minimum-maximum) value, and categorical variables as number (%). The compliance of the data to normal distribution was tested with the Shapiro-Wilk test. The Mann-Whitney test was used when comparing continuous variables in groups. The Chi-square test was used in the analysis of categorical variables. While testing the diagnostic value of the indices, ROC analysis was used, and area under curve (AUC) was presented with 95% confidence intervals (CI). Youden’s index was used while determining the optimum cutoff value, and diagnostic accuracy criteria for the cutoff were presented. RPL risk was given as odds ratio (OR) according to the index cutoff points determined. A P value of <0.05 was significant in all statistical tests. While determining post hoc powers for primary outcomes (BRI, ABSI, WtHR), effect sizes were taken as 0.311, 0.442, and 0.362, respectively. Type-I error was taken as 0.05 and post hoc powers found as 74.0%, 95.5%, and 85.1%, respectively. While determining the difference between groups, the sample size was adequate. For post hoc power calculation, G’power 3.1.9.2 was used.

3 RESULTS

The demographic and characteristics of both groups are shown in Table 1. The BMI had no statistically significant difference between groups (P = .276). According to BMI classification in the URPL group, 5 (3.6%) patients were underweight, 68 (49.3%) patients were normal weight, 39 (28.3%) patients were overweight, 23 (16.7%) patients were obese, and 3 (2.2%) patients were in the massive obese group. In the control group, 4 (2.9%) patients were underweight, 76 (54.7%) patients were normal weight, 37 (26.6%) patients were overweight, 20 (14.4%) patients were obese, and 2 (1.4%) patients were in the massive obese group. There was no significant difference in terms of BMI calcification in the subgroups (P > .05).

54 (39.1%) patients in the URPL group had at least one live birth in their medical history, and 74% of these patients had a normal vaginal delivery. All patients in the control group had at least one live birth, and 71.9% of the patients had delivered vaginally. There was no statistically significant difference in terms of delivery type (P = .695).

When AMH≤1 and AMH≥1 were compared, the number of patients with AMH≤1 was more common in the URPL group; the difference was not statistically significant (P = .235). Similarly, among the poor ovarian reserve markers, serum FSH≤11 and serum E₂≥60 values did not show a significant difference between the URPL and control groups (P > .05) (Table 1).

As BMI increased, the number of patients with AMH≤1 ng/mL increased for both the URPL and control groups (P < .01). While AMH≤1 was observed in 8.3% of the patients with normal BMI,
FIGURE 1 ROC curve of BRI, ABSI, WtHR and BMI: BRI, ABSI, WtHR have a diagnostic value for URPL (P < .05), BMI had no diagnostic value (P > .05).

Table 3. The URPL rate had been significantly increased in the patients above the cutoff value for all three indexes (P < .05).

4 | DISCUSSION

This study demonstrates that ABSI, BRI, and WtHR are effective in predicting URPL, and demonstrates that indexes showing body fat distribution should be used more effectively in the etiology of URPL instead of or with BMI.

BMI, which is used for the diagnosis and classification of obesity, is insufficient for showing fat-muscle separation and body fat distribution. Using different indexes instead of BMI in determining the risk of obesity-related diseases has been the subject of multiple studies. The role of this new indexes in predicting coronary artery disease, diabetes mellitus, and metabolic syndrome has been investigated, and they have been found to be in a stronger relationship than BMI.

RPL, which in 50% of cases is of unknown etiology, making it impossible for patients and physicians to determine future pregnancy outcomes, may cause serious emotional stress and depression for patients. It is known that obesity increases the risk of first trimester and recurrent pregnancy loss. Therefore, studies have been conducted on the etiology of RPL, and its relationship with obesity has been examined using BMI.

In this study, the relationship between BRI, ABSI, and WtHR with URPL, their potential superiority to BMI, and its relationship with ovarian reserve have been investigated. The relationship with URPL and an index (other than BMI) that may be effective in showing the diagnosis of obesity and fat distribution has not been investigated before in the literature. Our work is a first in this respect.

Obesity is thought to have a negative effect on female fertility by affecting the hypothalamic-pituitary-gonadal-hormonal axis, oocyte quality, embryo development, and endometrial receptivity.

According to Cavalcante et al. when the patients were classified according to BMI in the meta-analysis, the relationship between the obese group and RPL was seen, but the risk was not determined in the overweight and underweight groups. Metwally et al. reported that recurrent pregnancy loss is more common in the obese and overweight groups when RPL patients are classified according to BMI.

Lo et al. in their study using BMI groups, found that RPL risk increased in the obese group, while RPL risk did not change in the overweight and underweight groups. It has been reported that central obesity is more effective than BMI in terms of maternal and fetal complications. However, we did not find any study in the literature showing the relationship between central obesity and RPL. Also, considering the difference between BMI classes and RPL, we thought it would be more decisive to study the relationship between URPL and central obesity and anthropometric indices that show better muscle-fat separation, considering that various combinations of height and weight can reach the same BMI.

Some studies also found that WC and WtHR are better markers than BMI in obesity-related diseases. This is thought to be
because WC and WtHR are related to unhealthy weight distribution and are more effective than BMI in showing central fat distribution. ABSI, which was developed by using BMI and WtHR together, was found to be more effective in predicting the risk of premature death than BMI. In a study, WC and WtHR were related to unhealthy weight distribution and are more effective than BMI in showing central fat distribution.

In metabolic syndrome, the potency of ABSI was found to be higher predictive potency than BMI for diabetes mellitus. In another study, lower compared to BMI and WtHR, while BRI was reported to be the most effective index in predicting metabolic syndrome. Another study showed that while nine patients were followed in patients with normal BMI above the BRI cutoff value, all of them were in the URPL group. In light of these results, the risk of URPL must increase with the accumulation of body fat distribution in the central region, even in patients who are calculated as a normal BMI group and who are thought to have excluded the effect of obesity on URPL, and we think that this should be considered.

It has been reported that diminished ovarian reserve (DOR) can be effective on RPL by affecting oocyte quality and oocyte number. In a meta-analysis results, it was stated that there is a relationship between DOR and RPL, especially URPL. According to the results of the same study, it has been reported that low AMH levels (<1 ng/mL) and RLP are related, and the relationship between FSH and E2 values is not clear. Atasever et al. found in their study that low AMH and high FSH values were associated with RPL. In another study, a significant relationship was found between RPL and AMH, but no significant relationship was found with FSH.

The mechanism of action of obesity on ovarian reserve has not been clearly explained in the literature. The results differ according to the reserve tests used, patient population, and obesity classification. Moslehi et al. reported in their meta-analysis that there is a negative relationship between obesity and AMH, but not with FSH. They concluded that the reduction of the ovarian reserve in obese patients with RPL history is in a closer relationship with AMH than the other reserve tests. In our study, AMH values were found to be significantly lower in the URPL group. While the number of patients with AMH≤1 ng/mL was higher in the URPL group, this difference was not statistically significant. FSH and E2 values did not differ significantly between the groups.

Although there was a negative relationship between AMH and all indexes in our study, no significant relationship was found for FSH and E2. When we look at the relationship between the AMH value and the indexes, lower AMH values were observed in the obese and massively obese patient group compared to the patients with a normal BMI, while the number of patients with AMH≤1 ng/mL was higher. The number of patients with AMH≤1 ng/mL showed a significant difference above and below the cutoff value calculated for BMI, ABSI, and WtHR. AMH decreased as the index values increased. As the bodyweight rose above normal, ovarian reserve and quality decreased; we think that the detected RPL increase depends on this. However, we did not detect that the central distribution of obesity has a greater effect than obesity alone on reserve tests. In other words, the power of other indices to affect reserve tests was not higher than BMI. In future studies with more patients, the effect of fat distribution on ovarian reserve in the URPL patient group using other ovarian reserve tests will be seen more clearly by determining age ranges and cutoff values.

The limited number of samples, especially for cutoff values calculated for indices, and relatively few patients in the underweight
and massive obese groups as a result of BMI classification are the limitations of the study.

5 | CONCLUSION

In conclusion, URPL is a devastating situation whose etiology has not fully resolved, and the subsequent pregnancy outcomes are difficult to predict by patients and clinicians. In this study, we demonstrated that BRI, ABSI, and WHHR have diagnostic value for URPL, as in obesity-related diseases. We think that the relationship between obesity and URPL can be explained more clearly by using more effective indexes in showing body fat distribution rather than BMI. It should be kept in mind that central obesity is associated with an increased risk of pregnancy loss even in patients with normal BMI for URPL, whose etiology is questioned in every detail. Therefore, central region weight control and prevention of central obesity should be recommended to both patients with high BMI groups and patients with normal BMI groups.

CONFLICT OF INTEREST

Tunay Kiremitli, Sevil Kiremitli, Pasa Ulug, Kemal Dinc, Kemine Uzel and Yusuf Kemal Arslan declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS

Tunay Kiremitli, Sevil Kiremitli involved in conception and design. Kemal Dinc involved in acquisition of data. Yusuf Kemal Arslan involved in analysis and interpretation of data. Sevil Kiremitli, Kemine Uzel involved in drafting the article. Pasa Ulug involved in revising it critically for important intellectual content. Tunay Kiremitli involved in final approval of the version to be published. We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. All authors read and approved the manuscript for publication.

ETHICAL APPROVAL

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments. Ethics committee approval was obtained from institutional review board of Erzincan Binali Yildirim University in 14.01.2021. Clinical Research Ethics Committee no: 01/01.

ORCID

Tunay Kiremitli i http://orcid.org/0000-0002-4531-827X

REFERENCES

1. Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98(5):1103-1111. https://doi.org/10.1016/j.fertnstert.2012.06.048

2. Jauiaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod. 2006;21(9):2216-2222. https://doi.org/10.1093/humrep/del150

3. Royal College of Obstetricians and Gynaecologists. Greentop Guideline 17. Recurrent Miscarriage, investigation and treatment of couples. 2011.

4. Stirrat GM. Recurrent miscarriage. Lancet. 1990;336(8716):673-675. https://doi.org/10.1016/0140-6736(90)92159-f

5. Goddijn M, Christensen OB, Elson J. Recurrent Pregnancy Loss, Guideline of European Society of Human Reproduction and Embryology, 2017.

6. WHO Consultation on Obesity (1997:Geneva, Switzerland). WHO. Obesity: preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997.

7. James WP. What are the health risks? The medical consequences of obesity and its health risks. Exp Clin Endocrinol Diabetes. 1998;106(Suppl 2):1-6. https://doi.org/10.1055/s-0029-1212028

8. Zain MM, Norman RJ. Impact of obesity on female fertility and fertility treatment. Womens Health (Lond). 2008;4(2):183-194. https://doi.org/10.2217/17455057.4.2.183

9. Korucu O, Kukulu K. The Effect of the Obesity on Reproductive System. TAF Prev Med Bull. 2011;10(2):231-238.

10. Björntorp P. Abdominal obesity and the development of noninsulin-dependent diabetes mellitus. Diabetes Metab Rev. 1988;4(6):615-622. https://doi.org/10.1002/dmr.5610040607

11. Maessen MF, Eijsvogels TM, Verheggies G, Hopman MT, Verbeek AL, de Vegt F. Entering a new era of body indices: the feasibility of a body shape index and body roundness index to identify cardiovascular health status. PLoS ONE. 2014;9(9):e107212. https://doi.org/10.1371/journal.pone.0107212

12. Melikeoglu M, Onar C, Tuzun S, Temizkan S, Orbay E. Comparison of new and old body shape indices to estimate body fat in obese and morbid obese Turkish females. Turk J Endocrinol Metab. 2020;24:1-8.

13. Chang Y, Guo X, Chen Y, et al. A body shape index and body roundness index: two new body indices to identify diabetes mellitus among rural populations in northeast china. BMC Public Health. 2015;19(15):794. https://doi.org/10.1186/s12889-015-2150-2

14. Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. PLoS ONE. 2012;7(7):e39504. https://doi.org/10.1371/journal.pone.0039504

15. Thomas DM, Bredlau C, Bosy-Westphal A, et al. Relationships between body roundness and body fat and visceral adipose tissue emerging from a new geometrical model. Obesity (Silver Spring). 2013;21(11):2264-2271. https://doi.org/10.1002/oby.20408

16. Stefanescu A, Revilla L, Lopez T, Sanchez SE, Williams MA, Gelaye B. Using A Body Shape Index (ABSI) and Body Roundness Index (BRI) to predict risk of metabolic syndrome in Peruvian adults. J Int Med Res. 2020;48(1):300060519848854. https://doi.org/10.1177/0300065019848854

17. Zhang K, Zhao Q, Li Y, et al. Feasibility of anthropometric indices to identify dyslipidemia among adults in Jilin Province: a cross-sectional study. Lipids Health Dis. 2018;17(1):6. https://doi.org/10.1186/s12944-017-0648-6

18. Penzias A, Aziz Z, Bendikson K, et al. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2016;106(4):1151-1157. https://doi.org/10.1016/j.fertnstert.2020.09.134

19. Committee opinion no. 618: Ovarian reserve testing. Obstet Gynecol. 2015;125(1):268-273. https://doi.org/10.1097/OGO.0000000000001121

20. Malhotra N, Bahadur A, Singh N, Kaliavani M, Mittal S. Does obesity compromise ovarian reserve markers? A clinician's perspective. Arch Gynecol Obstet. 2013;287(1):161-166. https://doi.org/10.1007/s00404-012-2528-7

21. Moslehi N, Shab-Bidar S, Ramezani Tehrani F, Mirmiran P, Azizi F. Is ovarian reserve associated with body mass index and obesity in reproductive aged women? A meta-analysis. Menopause. 2018;25(9):1046-1055. https://doi.org/10.1097/GME.0000000000001116
